• Je něco špatně v tomto záznamu ?

Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma

M. Eid, L. Ostřížková, L. Kunovský, D. Brančíková, Z. Kala, J. Hlavsa, P. Janeček, I. Kosíková, M. Blažková, O. Slabý, J. Mayer

. 2021 ; 68 (1) : 1-9. [pub] 20200903

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21011684

Pancreatic ductal adenocarcinoma (PDAC) is now the 11th most common cancer and in 2018 there were 458,918 new cases worldwide. In the Czech Republic, a total of 2,173 patients were diagnosed in 2015, ranking the second in incidence worldwide. In contrast to other malignancies, recent research has not brought any major breakthrough in the treatment of PDAC and hence the prognosis remains very serious. Radical resection is the only curative approach, but after the initiation of the standard pathological evaluation of the resected tissue, according to the Leeds protocol, 80% of the resections are R1 (resections with microscopically positive margins). The results of studies in patients with borderline resectable or locally advanced PDAC prefer neoadjuvant chemotherapy or chemoradiotherapy. This approach leads to a higher number of radical R0 resections and better survival. For neoadjuvant treatment in patients with primarily resectable PDAC, most results come from retrospective analysis or phase II trials. However, recently, data from three randomized clinical trials with neoadjuvant therapy for resectable PDAC were presented. These results support the use of chemotherapy or chemoradiotherapy prior to surgery. In the trials published to date, there are differences in chemotherapeutic regimens, cytostatic doses, and the definition of resectability. Thus, up-front resection with adjuvant chemotherapy is still the standard of care and a well-designed randomized trial using neoadjuvant therapy is now necessary.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21011684
003      
CZ-PrNML
005      
20210507103856.0
007      
ta
008      
210420s2021 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2020_200408N372 $2 doi
035    __
$a (PubMed)32880468
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Eid, Michal $u Department of Hematology, Oncology and Internal Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma / $c M. Eid, L. Ostřížková, L. Kunovský, D. Brančíková, Z. Kala, J. Hlavsa, P. Janeček, I. Kosíková, M. Blažková, O. Slabý, J. Mayer
520    9_
$a Pancreatic ductal adenocarcinoma (PDAC) is now the 11th most common cancer and in 2018 there were 458,918 new cases worldwide. In the Czech Republic, a total of 2,173 patients were diagnosed in 2015, ranking the second in incidence worldwide. In contrast to other malignancies, recent research has not brought any major breakthrough in the treatment of PDAC and hence the prognosis remains very serious. Radical resection is the only curative approach, but after the initiation of the standard pathological evaluation of the resected tissue, according to the Leeds protocol, 80% of the resections are R1 (resections with microscopically positive margins). The results of studies in patients with borderline resectable or locally advanced PDAC prefer neoadjuvant chemotherapy or chemoradiotherapy. This approach leads to a higher number of radical R0 resections and better survival. For neoadjuvant treatment in patients with primarily resectable PDAC, most results come from retrospective analysis or phase II trials. However, recently, data from three randomized clinical trials with neoadjuvant therapy for resectable PDAC were presented. These results support the use of chemotherapy or chemoradiotherapy prior to surgery. In the trials published to date, there are differences in chemotherapeutic regimens, cytostatic doses, and the definition of resectability. Thus, up-front resection with adjuvant chemotherapy is still the standard of care and a well-designed randomized trial using neoadjuvant therapy is now necessary.
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    12
$a duktální karcinom slinivky břišní $x farmakoterapie $x chirurgie $7 D021441
650    _2
$a lidé $7 D006801
650    _2
$a neoadjuvantní terapie $7 D020360
650    12
$a nádory slinivky břišní $x farmakoterapie $x chirurgie $7 D010190
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ostřížková, Lenka $u Department of Hematology, Oncology and Internal Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kunovský, Lumír $u Department of Surgery, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Gastroenterology and Internal Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Brančíková, Dagmar $u Department of Hematology, Oncology and Internal Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kala, Zdeněk $u Department of Surgery, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Hlavsa, Jan $u Department of Surgery, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Janeček, Pavel $u Department of Surgery, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kosíková, Ivana $u Department of Hematology, Oncology and Internal Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Blažková, Monika $u Department of Hematology, Oncology and Internal Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Slabý, Ondřej $u Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Mayer, Jiří $u Department of Hematology, Oncology and Internal Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 68, č. 1 (2021), s. 1-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32880468 $y Pubmed
910    __
$a ABA008 $b A 1194 $c 659 $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507103855 $b ABA008
999    __
$a ok $b bmc $g 1650147 $s 1132063
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 68 $c 1 $d 1-9 $e 20200903 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace